))
The World in a Grain of Sand: Amylyx Pharmaceuticals
Manage episode 382347637 series 3526488
Content provided by KdT Ventures. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by KdT Ventures or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
13 episodes
Share
